Alexion pushes for judgment in EmblemHealth's US antitrust suit over Soliris
MLex Summary: Alexion Pharmaceuticals filed a reply in support of its motion for judgment on pleadings in EmblemHealth's US antitrust suit over Alexion's alleged unlawful delaying of biosimilar competition for its...To view the full article, register now.
Already a subscriber? Click here to view full article